Acquisition - January 8, 2016
Sobi gains commercial rights from Pharma Swiss
Swedish Orphan Biovitrum AB has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor®, Deflux® and Solesta® in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia. “I am delighted that we have expanded our successful partnership with PharmaSwiss and provide patients and physicians with […]
Pharma Business - August 19, 2015
Approval in Australia for Sobi’s Kineret
Sobi together with its Australian partner, A. Menarini Australia Pty Ltd have received marketing authorisation in Australia for Kineret (anakinra) for the treatment of systemic juvenile idiopathic arthritis (SJIA), which is a rare form of juvenile chronic arthritis. “We are pleased and encouraged by this approval which was achieved through a fruitful collaboration between physicians, […]
Drug Development Pharma - July 1, 2015
EC Approves Sobi Drug for HT-1
The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone). The orphan drug treats Hereditary Tyrosinaemia type-1 (HT-1), a rare genetic and potentially fatal condition that affects infants and children and can result in liver and kidney failure if untreated, according to PMLiVE. “The European Medicines Agency has called […]
Agreement - June 28, 2015
Sobi Dismisses Takeover Talk
Sobi’s board of directors has ended any discussions about the possible sale of all shares issued by the company. “Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio,” the company said in a statement. Sobi had a market value […]
Collaboration - June 5, 2015
Biogen Files MAA for Hemophilia Drug
Swedish Orphan Biovitrum AB (Sobi’s) partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialization of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa, according to Sobi. The MAA filing with […]
Acquisition - April 28, 2015
Unnamed Bidders Approach Sobi
Swedish Orphan Biovitrum (Sobi) has been approached by bidders, but the company is not revealing the names of the interested parties. The company recently issued a statement saying “that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.” Word of the proposed takeover […]
